- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03094260
Light Therapy and Binge Eating Disorder Treatment (BED Light Study)
Interest of Light Therapy in the Treatment of Binge Eating Disorder: Prospective Controlled Randomized Double-blind Trial
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bron, France, 69500
- HCL Centre REférent pour l'Anorexie et les Troubles du Comportement Alimentaire de Lyon (CREATyon)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged between 18 and 55 years old
- Binge eating disorders or other eating disorders according to DSM V criteria
- Patient with BES score (with " Bing Eating Scale " ) > 18
- Patient with BMI > 18.5 kg/m2
- Patient who agrees to be included in the study and who signs the informed consent form
- Patient affiliated to a healthcare insurance plan
Exclusion Criteria:
- Patients with other psychiatric comorbidities, including a disorder bipolar mood
- Unstabilized diabetic patient with or retinopathy
- Patient with sleep disorder (delay or phase inversion)
- Patient with psychotropic treatment unstabilized (except anxiolytic treatment)
- Recent eye surgery or eye problem preventing exposure to bright light.
- Medication making the skin more sensitive to light (eg. Tablets against malaria)
- Patient who does not understand French/is unable to give consent
- Mentally unbalanced patients, under supervision or guardianship
- Patient already included in a research study
- Pregnancy or desire to be pregnant during the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: High intensity light therapy
Treatment with light therapy in high intensity (10,000 lux)
|
Treatment with light therapy in high intensity (10,000 lux), daily for 30 days between 6 am and 9 am for 30 minutes. Le device is placed at arm's length (at approximately 50-75cm from the eyes) within the field of vision. The light must bathe the face To ensure the light reaches your eyes, this appliance has a stand that can be set to a variable angle. If subject is sitting higher or standing and the top edge of the appliance is below eye level, the appliance will be placed in a tilted position so that its light points further upwards and reaches the eyes. If subject is sitting at a table or desk and the top edge of the appliance is above eye level. The appliance can be placed in a more upright position. |
|
PLACEBO_COMPARATOR: Low intensity light therapy
Treatment with light therapy in low intensity (<500 lux)
|
Treatment with light therapy in low intensity (<500 lux), daily for 30 days between 6 am and 9 am for 30 minutes. Le device is placed at arm's length (at approximately 50-75cm from the eyes) within the field of vision. The light must bathe the face To ensure the light reaches your eyes, this appliance has a stand that can be set to a variable angle. If subjectis sitting higher or standing and the top edge of the appliance is below eye level, the appliance will be placed in a tilted position so that its light points further upwards and reaches the eyes. If subject is sitting at a table or desk and the top edge of the appliance is above eye level. The appliance can be placed in a more upright position. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comparison of the number of hyperphagic access, over 7 consecutive days, before starting therapy with light therapy and discontinuation of treatment
Time Frame: Day-7 to Day-1 period (before Day 0) compared to Day23 to Day30 period (after Day 0)
|
The number of hyperphagic access will be determined using a crisis agenda filled out by patients each day
|
Day-7 to Day-1 period (before Day 0) compared to Day23 to Day30 period (after Day 0)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comparison of the number of hyperphagic access, over 7 consecutive days, before starting therapy with light therapy and 30 days after discontinuation of treatment
Time Frame: Day-7 to Day-1 period compared to Day23 to Day30 period
|
The number of hyperphagic access will be determined using a crisis agenda filled out by patients each day
|
Day-7 to Day-1 period compared to Day23 to Day30 period
|
|
Characteristics of hyperphagic access (severity of the disorder)
Time Frame: Day 0
|
Evaluation of the severity of bulimic hyperphagia by the Bing Eating Scale.
|
Day 0
|
|
Characteristics of hyperphagic access (severity of the disorder)
Time Frame: Day 30
|
Evaluation of the severity of bulimic hyperphagia by the Bing Eating Scale.
|
Day 30
|
|
Characteristics of hyperphagic access (severity of the disorder)
Time Frame: Day 60
|
Evaluation of the severity of bulimic hyperphagia by the Bing Eating Scale.
|
Day 60
|
|
Characteristics of hyperphagic access (duration of crisis)
Time Frame: Day 0
|
Evaluation of the duration,by the crisis agenda.
|
Day 0
|
|
Characteristics of hyperphagic access (duration of crisis)
Time Frame: Day 30
|
Evaluation of the duration,by the crisis agenda.
|
Day 30
|
|
Characteristics of hyperphagic access (duration of crisis)
Time Frame: Day 60
|
Evaluation of the duration,by the crisis agenda.
|
Day 60
|
|
Characteristics of hyperphagic access (amount of food ingested )
Time Frame: Day 0
|
Evaluation of the quantity of food ingested during the hyperphagic access and the delays between two accesses by the crisis agenda.
|
Day 0
|
|
Characteristics of hyperphagic access (amount of food ingested )
Time Frame: Day 30
|
Evaluation of the quantity of food ingested during the hyperphagic access and the delays between two accesses by the crisis agenda.
|
Day 30
|
|
Characteristics of hyperphagic access (amount of food ingested )
Time Frame: Day 60
|
Evaluation of the quantity of food ingested during the hyperphagic access and the delays between two accesses by the crisis agenda.
|
Day 60
|
|
Characteristics of hyperphagic access ( evolution of factors triggering)
Time Frame: Day 0
|
Evaluation of the factors triggering by the "START" scale.
|
Day 0
|
|
Characteristics of hyperphagic access ( evolution of factors triggering)
Time Frame: Day 30
|
Evaluation of the factors triggering by the "START" scale.
|
Day 30
|
|
Characteristics of hyperphagic access ( evolution of factors triggering)
Time Frame: Day 60
|
Evaluation of the factors triggering by the "START" scale.
|
Day 60
|
|
Characteristics of hyperphagic access (severity of the disorder, duration of crisis, amount of food ingested and evolution of factors triggering)
Time Frame: Day 30
|
Evaluation of the severity of bulimic hyperphagia by the Bing Eating Scale.
Evaluation of the duration, the quantity of food ingested during the hyperphagic access and the delays between two accesses by the crisis agenda.
Evaluation of the factors triggering by the "START" scale.
|
Day 30
|
|
Comparison of the number of hyperphagic access, over 7 consecutive days, before starting therapy with light therapy and 30 days after discontinuation of treatment
Time Frame: Day-7 to Day-1 period (before Day 0) compared to Day53 to Day60 period (after Day 0)
|
The number of hyperphagic access will be determined using a crisis agenda filled out by patients each day
|
Day-7 to Day-1 period (before Day 0) compared to Day53 to Day60 period (after Day 0)
|
|
Symptomatic development of BED
Time Frame: Day 0
|
The symptomatic development of BED will be measured by evaluating :
|
Day 0
|
|
Symptomatic development of BED
Time Frame: Day 30
|
The symptomatic development of BED will be measured by evaluating the composite:
|
Day 30
|
|
Symptomatic development of BED
Time Frame: Day 60
|
The symptomatic development of BED will be measured by evaluating the composite:
|
Day 60
|
|
Evolution of other psychological parameters related to BED
Time Frame: Day 0
|
The evolution of other psychological parameters will be measured by evaluating the composite :the mood from the Beck Depression Inventory scale, the anxiety from the "State Trait Anxiety Inventory or STAI-Y" scale, the clinical impulsivity from the "UPPS-P shortcut" scale
|
Day 0
|
|
Evolution of other psychological parameters related to BED
Time Frame: Day 30
|
The evolution of other psychological parameters will be measured by evaluating the composite the mood from the Beck Depression Inventory scale, the anxiety from the "State Trait Anxiety Inventory or STAI-Y" scale, the clinical impulsivity from the "UPPS-P shortcut" scale
|
Day 30
|
|
Evolution of other psychological parameters related to BED
Time Frame: Day 60
|
The evolution of other psychological parameters will be measured by evaluating the composite mood from the Beck Depression Inventory scale, the anxiety from the "State Trait Anxiety Inventory or STAI-Y" scale, the clinical impulsivity from the "UPPS-P shortcut" scale
|
Day 60
|
|
Evolution of attentional cognitive profiles and impulsivity
Time Frame: Day 0
|
The evolution of attentional and impulsive cognitive profiles will be measured from a computerized neurocognitive test battery whose order will be randomly fixed.
The tests will be STROOP, The Go / No Go, The Stop Signal Task, The Balloon Analog Risk Task, The Prospective Time Estimation Task, The Set Switching Task
|
Day 0
|
|
Evolution of attentional cognitive profiles and impulsivity
Time Frame: Day 30
|
The evolution of attentional and impulsive cognitive profiles will be measured from a computerized neurocognitive test battery whose order will be randomly fixed.
The tests will be STROOP, The Go / No Go, The Stop Signal Task, The Balloon Analog Risk Task, The Prospective Time Estimation Task, The Set Switching Task
|
Day 30
|
|
Evolution of attentional cognitive profiles and impulsivity
Time Frame: Day 60
|
The evolution of attentional and impulsive cognitive profiles will be measured from a computerized neurocognitive test battery whose order will be randomly fixed.
The tests will be STROOP, The Go / No Go, The Stop Signal Task, The Balloon Analog Risk Task, The Prospective Time Estimation Task, The Set Switching Task
|
Day 60
|
|
Evolution of appetite for different categories of food
Time Frame: Day 0
|
The evolution of appetite for different categories of food will be measured from a computerized task: the Leed Food Preference Questionnaire (LFPQ).
A description of the test is available at: https://www.millisecond.com/download/library/
|
Day 0
|
|
Evolution of appetite for different categories of food
Time Frame: Day 30
|
The evolution of appetite for different categories of food will be measured from a computerized task: the Leed Food Preference Questionnaire (LFPQ).
A description of the test is available at: https://www.millisecond.com/download/library/
|
Day 30
|
|
Evolution of appetite for different categories of food
Time Frame: Day 60
|
The evolution of appetite for different categories of food will be measured from a computerized task: the Leed Food Preference Questionnaire (LFPQ).
A description of the test is available at: https://www.millisecond.com/download/library/
|
Day 60
|
|
Biological parameters may be impacted or mediated by part of the treatment efficiency
Time Frame: Day 0
|
Inflammation parameters, glucose, insulinemia, insulin resistance, Profile of lipid abnormalities, 1-25-OH vitamin D3
|
Day 0
|
|
Biological parameters may be impacted or mediated by part of the treatment efficiency
Time Frame: Day 30
|
Inflammation parameters, glucose, insulinemia, insulin resistance, Profile of lipid abnormalities, 1-25-OH vitamin D3
|
Day 30
|
|
Weight (kilogramm)
Time Frame: Day 0
|
Weight will be expressed in absolute value
|
Day 0
|
|
Weight (kilogramm)
Time Frame: Day 30
|
Weight will be expressed in absolute value
|
Day 30
|
|
Weight (kilogramm)
Time Frame: Day 60
|
Weight will be expressed in absolute value
|
Day 60
|
|
Observance rate to light therapy
Time Frame: day1 to day30
|
The assessment of the adherence rate will be quantified by the average number of lux received over the 30 days of treatment.
The exposure (expressed in lux number / session) in lux will be measured and recorded using a luxmeter
|
day1 to day30
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Diane MORFIN, MD, Hospices Civils de Lyon Centre REférent pour l'Anorexie et les Troubles du Comportement Alimentaire de Lyon (CREATyon)
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 69HCL16_0626
- 2016-A01768-43 (OTHER: ID-RCB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Binge-Eating Disorder
-
University of Sao Paulo General HospitalActive, not recruitingBinge Eating DisorderBrazil
-
University of North Carolina, Chapel HillThe Hilda & Preston Davis Foundation; Global Foundation for Eating DisordersCompletedEating Disorder | Binge-eating DisorderUnited States
-
ShireCompleted
-
Lindner Center of HOPEUniversity of CincinnatiCompleted
-
Axsome Therapeutics, Inc.Enrolling by invitationBinge-Eating DisorderUnited States
-
BioprojetCompleted
-
Sao Jose do Rio Preto Medical SchoolFundação de Amparo à Pesquisa do Estado de São PauloCompletedBinge-Eating Disorder | Eating Disorders | Eating Behavior | Eating Disorder | Binge Eating Disorder Associated With ObesityBrazil
-
Axsome Therapeutics, Inc.RecruitingBinge-Eating DisorderUnited States
-
Otsuka Pharmaceutical Development & Commercialization...CompletedBinge-Eating DisorderUnited States
-
Ali RezaiActive, not recruiting
Clinical Trials on High intensity bright light therapy
-
Peking University Sixth HospitalBeijing HuiLongGuan Hospital; Yan'an Third People's HospitalRecruiting
-
National Center for Complementary and Integrative...Completed
-
VA Office of Research and DevelopmentRecruiting
-
Sunnybrook Health Sciences CentreCompletedMajor Depressive Disorder | Seasonal Affective Disorder | NeuroimagingCanada
-
Hospital Authority, Hong KongUnknown
-
Medical University of ViennaCompletedMyalgic Encephalomyelitis/Chronic Fatigue SyndromeAustria
-
M.D. Anderson Cancer CenterTerminatedAdvanced CancersUnited States
-
State University of New York at BuffaloOncology Nursing SocietyCompletedFatigue | Sleep Disturbance | Circadian DysregulationUnited States
-
Medical University of ViennaNational Bank of AustriaUnknownMultiple Sclerosis | FatigueAustria
-
University of OuluOulu University Hospital; University of Eastern Finland; ODL Terveys Oy; Valkee OyUnknownSeasonal Affective DisorderFinland